アブストラクト
| Title | イメグリミン - 糖尿病 |
|---|---|
| Subtitle | 特集 心腎連関から新薬まで! 心×腎疾患の薬物治療 心腎領域の新薬 |
| Authors | 松下真弥 |
| Authors (kana) | |
| Organization | 国立国際医療研究センター病院糖尿病内分泌代謝科 |
| Journal | 月刊薬事 |
| Volume | 64 |
| Number | 4 |
| Page | 763-767 |
| Year/Month | 2022 / 3 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Points]●イメグリミンは, 血糖値依存的なインスリン分泌を促進し, 血糖値を改善させる. ●日本人2型糖尿病患者は欧米人と比較してインスリン分泌能の低下した症例が多く, イメグリミンの良い適応と考えられる. ●消化器症状の副作用が報告されており, 症状が出現した際は中止を検討する. ●動物実験では, イメグリミンを投与することで心機能や腎機能の改善も報告されているが, 臨床研究などでの検証が必要である. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Yendapally R, et al : A review of phenformin, metformin, and imeglimin. Drug Dev Res, 81 : 390-401, 2020
- 2) Vial G, et al : The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells. Endocrinol Diabetes Metab, 4 : e00211, 2021
- 3) Hallakou-Bozec S, et al : Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action. PLoS One, 16 : e0241651, 2021
- 4) Hallakou-Bozec S, et al : Imeglimin preserves islet β-cell mass in Type 2 diabetic ZDF rats. Endocrinol Diabetes Metab, 4 : e00193, 2020
- 5) Konkwo C, et al : Imeglimin : current development and future potential in type 2 diabetes. Drugs, 81 : 185-190, 2021
残りの12件を表示する
- 6) Vial G, et al : Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Diabetes, 64 : 2254-2264, 2015
- 7) Perry RJ, et al : Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents. Am J Physiol Endocrinol Metab, 311 : E461-E470, 2016
- 8) Kitakata H, et al : Imeglimin prevents heart failure with preserved ejection fraction by recovering the impaired unfolded protein response in mice subjected to cardio-metabolic stress. Biochem Biophys Res Commun, 572 : 185-190, 2021
- 9) Lachaux M, et al : Short-and long-term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome. Endocrinol Diabetes Metab, 3 : e00128, 2020
- 10) Fouqueray P, et al : The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inade-quately controlled with metformin monotherapy. Diabetes Care, 36 : 565-568, 2013
- 11) Fouqueray P, et al : The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inade-quately controlled with sitagliptin monotherapy. Diabetes Care, 37 : 1924-1930, 2014
- 12) Dubourg J, et al : Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes : A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial. Diabetes Obes Metab, 23 : 800-810, 2021
- 13) Dubourg J, et al : Efficacy and safety of imeglimin monotherapy versus placebo in Japanese patients with type 2 diabetes(TIMES 1) : A double-blind, randomized, placebo-controlled, parallel-group, multicenter phase 3 trial. Diabetes Care, 44 : 952-959, 2021
- 14) Pacini G, et al : Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes. Diabetes Obes Metab, 17 : 541-545, 2015
- 15) Fukushima M, et al : Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract, 66(Suppl. 1) : S37-S43, 2004
- 16) 日本糖尿病学会・編著 : 糖尿病治療ガイド2020-2021. 文光堂, p33, 2020
- 17) Gerich JE : Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus. Mayo Clin Proc, 78 : 447-456, 2003
